Gilbert & Cook Inc. Acquires 210 Shares of Johnson & Johnson (JNJ)
Gilbert & Cook Inc. raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 5.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,933 shares of the company’s stock after buying an additional 210 shares during the period. Gilbert & Cook Inc.’s holdings in Johnson & Johnson were worth $490,000 at the end of the most recent quarter.
Several other large investors have also made changes to their positions in the stock. Norges Bank acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $3,220,322,000. State Street Corp increased its stake in shares of Johnson & Johnson by 4.3% in the first quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after buying an additional 6,656,371 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $277,294,000. Fiera Capital Corp increased its stake in shares of Johnson & Johnson by 16.9% in the fourth quarter. Fiera Capital Corp now owns 4,249,504 shares of the company’s stock worth $489,585,000 after buying an additional 615,219 shares in the last quarter. Finally, Korea Investment CORP increased its stake in shares of Johnson & Johnson by 38.9% in the first quarter. Korea Investment CORP now owns 2,130,033 shares of the company’s stock worth $265,296,000 after buying an additional 596,134 shares in the last quarter. 66.10% of the stock is owned by institutional investors and hedge funds.
Shares of Johnson & Johnson (NYSE:JNJ) traded up 0.82% during mid-day trading on Wednesday, hitting $134.48. 1,470,671 shares of the stock were exchanged. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $137.08. The firm has a market cap of $360.94 billion, a price-to-earnings ratio of 22.75 and a beta of 0.78. The company’s 50-day moving average is $132.93 and its 200-day moving average is $126.81.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.04. The firm had revenue of $18.84 billion during the quarter, compared to analysts’ expectations of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter last year, the company posted $1.74 EPS. Equities research analysts anticipate that Johnson & Johnson will post $7.18 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th will be given a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 2.52%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s payout ratio is presently 56.76%.
COPYRIGHT VIOLATION NOTICE: “Gilbert & Cook Inc. Acquires 210 Shares of Johnson & Johnson (JNJ)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/gilbert-cook-inc-acquires-210-shares-of-johnson-johnson-jnj/1495656.html.
JNJ has been the subject of a number of recent research reports. J P Morgan Chase & Co raised shares of Johnson & Johnson from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $123.64 to $140.00 in a research report on Monday, May 15th. UBS AG reaffirmed a “buy” rating and set a $148.00 price objective (up previously from $136.00) on shares of Johnson & Johnson in a research report on Wednesday, July 19th. Alembic Global Advisors downgraded shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research report on Friday, July 21st. Vetr downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $128.82 price objective for the company. in a research report on Monday, May 15th. Finally, BTIG Research reaffirmed a “hold” rating on shares of Johnson & Johnson in a research report on Wednesday, April 19th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $134.12.
In other Johnson & Johnson news, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the sale, the vice president now owns 226,693 shares in the company, valued at approximately $30,993,466.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the sale, the vice president now owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. Company insiders own 0.19% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.